Blocking Epac1 Halts Lung Scarring by Preserving a Key Anti-Fibrosis Protein
A new Epac1 inhibitor, AM-001, reverses pulmonary fibrosis by preventing NEDD8-driven destruction of the protective protein FoxO3a.
Summary
Idiopathic pulmonary fibrosis (IPF) is a fatal lung-scarring disease with no cure. Researchers found that a signaling protein called Epac1 is abnormally elevated in IPF lung tissue and drives fibroblast proliferation and scar formation. By blocking Epac1—either genetically or with a small-molecule inhibitor called AM-001—the team reduced fibrosis markers, blunted TGF-β and IL-6 signaling, and protected mice from bleomycin-induced lung injury. The key mechanism involves the neddylation pathway: Epac1 promotes attachment of the protein NEDD8 to FoxO3a, tagging it for degradation. AM-001 blocks this process, restoring FoxO3a levels and its anti-fibrotic, cell-cycle-inhibiting functions. Results were validated in human IPF fibroblasts and precision-cut lung slices.
Detailed Summary
Idiopathic pulmonary fibrosis is a progressive, age-related disease that destroys lung architecture, causes respiratory failure, and carries a median survival of only 3.8 years. Only two approved therapies exist, and neither reverses existing fibrosis. There is an urgent need for new mechanistic targets and druggable pathways.
This study investigated exchange protein directly activated by cAMP 1 (Epac1), a second messenger effector alongside protein kinase A (PKA). While PKA has long been known to suppress fibroblast activation, Epac1's role in lung fibrosis had not been explored. The team examined lung tissue from eight IPF patients and eight healthy donors, primary IPF fibroblasts, bleomycin-treated mice, Epac1 knockout mice, and ex vivo precision-cut lung slices from PF patients—providing a comprehensive multi-model interrogation.
Epac1 expression was consistently elevated in IPF lung tissue, fibrotic fibroblasts, and bleomycin-challenged mouse lungs. Genetic knockdown via lentiviral shRNA and pharmacological inhibition with the small molecule AM-001 both significantly reduced fibroblast proliferation and suppressed key profibrotic markers including α-smooth muscle actin (α-SMA), TGF-β/SMAD2/3, and IL-6/STAT3 signaling. In the bleomycin mouse model, AM-001 treatment substantially protected lung architecture and reduced fibrosis scores. Ex vivo IPF lung slices treated with AM-001 for 10 days similarly showed reduced fibrotic gene expression and collagen deposition by Masson's trichrome staining.
The central mechanistic finding involves the neddylation pathway. Global gene expression profiling of Epac1-deficient cells identified downregulation of neddylation pathway components. Epac1 activity promotes NEDD8 conjugation to FoxO3a—a transcription factor that normally inhibits cell-cycle progression and protects against fibrosis. NEDD8 attachment flags FoxO3a for proteasomal degradation. AM-001 blocks this interaction, preserving FoxO3a levels and restoring its anti-fibrotic function. This was corroborated by use of pevonedistat (MLN4924), a NAE inhibitor, which mimicked the protective effects of Epac1 inhibition. Additionally, AM-001 limited proliferation of lung-infiltrating monocytes, suggesting an immune-modulatory component to its anti-fibrotic benefit.
These results position Epac1 as a previously unrecognized driver of IPF pathology and AM-001 as a promising candidate therapeutic. The identification of the NEDD8–FoxO3a axis as a downstream effector adds a novel layer to fibrosis biology. However, AM-001 has not yet entered clinical trials, and translation from mouse models to human disease will require careful dose optimization and safety profiling.
Key Findings
- Epac1 is significantly overexpressed in lung tissue and fibroblasts from IPF patients and bleomycin-treated mice.
- AM-001, a selective Epac1 inhibitor, reduces fibroblast proliferation and suppresses TGF-β/SMAD2/3 and IL-6/STAT3 profibrotic signaling.
- Epac1 drives NEDD8-mediated neddylation and degradation of FoxO3a; AM-001 restores FoxO3a levels and its cell-cycle-inhibitory function.
- AM-001 protected against bleomycin-induced pulmonary fibrosis in mice and reduced fibrosis markers in human ex vivo lung slices.
- Epac1 inhibition also limits lung-infiltrating monocyte proliferation, suggesting additional immune-modulatory anti-fibrotic effects.
Methodology
The study used IPF patient lung tissue (n=8) and healthy donor controls (n=8), primary human IPF fibroblasts, bleomycin-induced mouse models, Epac1 knockout mice, lentiviral shRNA knockdown, and ex vivo precision-cut lung slices from three PF patients. Pharmacological modulation was assessed with the Epac1 inhibitor AM-001 and the NAE inhibitor pevonedistat. Outcomes included histology, Western blotting, flow cytometry, and global gene expression profiling.
Study Limitations
All in vivo data derive from the bleomycin mouse model, which incompletely recapitulates human IPF progression and does not capture its chronic, spontaneous nature. Human ex vivo data come from only three PF patients, limiting statistical power. AM-001 has not been evaluated in formal toxicology or pharmacokinetic studies required for clinical development.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.